Nano Research

, Volume 12, Issue 1, pp 41–48 | Cite as

Photo-controlled release of paclitaxel and model drugs from RNA pyramids

  • Congcong Xu
  • Hui Li
  • Kaiming Zhang
  • Daniel W. Binzel
  • Hongran Yin
  • Wah Chiu
  • Peixuan GuoEmail author
Research Article


Stimuli-responsive release of drugs from a nanocarrier in spatial-, temporal-, and dosage-controlled fashions is of great interest in the pharmaceutical industry. Paclitaxel is one of the most effective and popular chemotherapeutic drugs against a number of cancers such as metastatic or nonmetastatic breast cancer, non–small cell lung cancer, refractory ovarian cancer, AIDS-related Kaposi’s sarcoma, and head and neck cancers. Here, by taking the advantage of RNA nanotechnology in biomedical and material science, we developed a three-dimensional pyramid-shaped RNA nanocage for a photocontrolled release of cargo, using paclitaxel as a model drug. The light-triggered release of paclitaxel or fluorophore Cy5 was achieved by incorporation of photocleavable spacers into the RNA nanoparticles. Upon irradiation with ultraviolet light, cargos were rapidly released (within 5 min). In vitro treatment of breast cancer cells with the RNA nanoparticles harboring photocleavable paclitaxel showed higher cytotoxicity as compared to RNA nanoparticles without the photocleavable spacer. The methodology provides proof of concept for the application of the light-triggered controlled release of drugs from RNA nanocages.


RNA nanotechnology controlled release paclitaxel drug delivery RNA nanoparticles Phi29 three-way junction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



The research in P. G.’s lab was supported by NIH grants R01EB019036, R01CA186100 and U01CA207946 to Peixuan Guo. The cryo-EM work was supported by NIH grants P41GM103832 (W. C.) and P50 GM103297 (W. C.). P. G.’s Sylvan G. Frank Endowed Chair position in Pharmaceutics and Drug Delivery is funded by the CM Chen Foundation. We would like to thank Dr. Farzin Haque and Dr. Daniel Jasinski for helpful discussions. We also would like to thank Dr. Yi Shu for synthesis of paclitaxel-N3.

Supplementary material

12274_2018_2174_MOESM1_ESM.pdf (2.7 mb)
Photo-controlled release of paclitaxel and model drugs from RNA pyramids


  1. [1]
    Karimi, M.; Ghasemi, A.; Sahandi, Z. P.; Rahighi, R.; Moosavi Basri, S. M.; Mirshekari, H.; Amiri, M.; Shafaei, P. Z.; Aslani, A.; Bozorgomid, M. et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem. Soc. Rev. 2016, 45, 1457–1501.CrossRefGoogle Scholar
  2. [2]
    Hoffman, A. S. Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation. Adv. Drug Deliv. Rev. 2013, 65, 10–16.CrossRefGoogle Scholar
  3. [3]
    Blum, A. P.; Kammeyer, J. K.; Rush, A. M.; Callmann, C. E.; Hahn, M. E.; Gianneschi, N. C. Stimuli-responsive nanomaterials for biomedical applications. J. Am. Chem. Soc. 2015, 137, 2140–2154.CrossRefGoogle Scholar
  4. [4]
    Rahoui, N.; Jiang, B.; Taloub, N.; Huang, Y. D. Spatio-temporal control strategy of drug delivery systems based nano structures. J. Control. Release 2017, 255, 176–201.CrossRefGoogle Scholar
  5. [5]
    Liu, D.; Yang, F.; Xiong, F.; Gu, N. The smart drug delivery system and its clinical potential. Theranostics 2016, 6, 1306–1323.CrossRefGoogle Scholar
  6. [6]
    Kahn, J. S.; Hu, Y. W.; Willner, I. Stimuli-responsive DNA-based hydrogels: From basic principles to applications. Acc. Chem. Res. 2017, 50, 680–690.CrossRefGoogle Scholar
  7. [7]
    Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12, 991–1003.CrossRefGoogle Scholar
  8. [8]
    Torchilin, V. P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014, 13, 813–827.CrossRefGoogle Scholar
  9. [9]
    Lin, Z. Q.; Gao, W.; Hu, H. X.; Ma, K.; He, B.; Dai, W. B.; Wang, X. Q.; Wang, J. C.; Zhang, X.; Zhang, Q. Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity. J. Control. Release 2014, 174, 161–170.CrossRefGoogle Scholar
  10. [10]
    Rapoport, N. Y.; Kennedy, A. M.; Shea, J. E.; Scaife, C. L.; Nam, K. H. Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J. Control. Release 2009, 138, 268–276.CrossRefGoogle Scholar
  11. [11]
    Alam, M. M.; Han, H. S.; Sung, S.; Kang, J. H.; Sa, K. H.; Al Faruque, H.; Hong, J.; Nam, E. J.; Kim, I. S.; Park, J. H. et al. Endogenous inspired biomineral-installed hyaluronan nanoparticles as pH-responsive carrier of methotrexate for rheumatoid arthritis. J. Control. Release 2017, 252, 62–72.CrossRefGoogle Scholar
  12. [12]
    Li, J.; Huo, M. R.; Wang, J.; Zhou, J. P.; Mohammad, J. M.; Zhang, Y. L.; Zhu, Q. N.; Waddad, A. Y.; Zhang, Q. Redox-sensitive micelles selfassembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 2012, 33, 2310–2320.CrossRefGoogle Scholar
  13. [13]
    Veetil, A. T.; Chakraborty, K.; Xiao, K.; Minter, M. R.; Sisodia, S. S.; Krishnan, Y. Cell-targetable DNA nanocapsules for spatiotemporal release of caged bioactive small molecules. Nat. Nanotechnol. 2017, 12, 1183–1189.CrossRefGoogle Scholar
  14. [14]
    Spring, B. Q.; Bryan, S. R.; Zheng, L. Z.; Mai, Z. M.; Watanabe, R.; Sherwood, M. E.; Schoenfeld, D. A.; Pogue, B. W.; Pereira, S. P.; Villa, E. et al. A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. Nat. Nanotechnol. 2016, 11, 378–387.CrossRefGoogle Scholar
  15. [15]
    Karimi, M.; Sahandi, Z. P.; Baghaee-Ravari, S.; Ghazadeh, M.; Mirshekari, H.; Hamblin, M. R. Smart nanostructures for cargo delivery: Uncaging and activating by light. J. Am. Chem. Soc. 2017, 139, 4584–4610.CrossRefGoogle Scholar
  16. [16]
    Bansal, A.; Zhang, Y. Photocontrolled nanoparticle delivery systems for biomedical applications. Acc. Chem. Res. 2014, 47, 3052–3060.CrossRefGoogle Scholar
  17. [17]
    Wang, Y. Y.; Deng, Y. B.; Luo, H. H.; Zhu, A. J.; Ke, H. T.; Yang, H.; Chen, H. B. Light-responsive nanoparticles for highly efficient cytoplasmic delivery of anticancer agents. ACS Nano 2017, 11, 12134–12144.CrossRefGoogle Scholar
  18. [18]
    Shim, G.; Ko, S.; Kim, D.; Le, Q. V.; Park, G. T.; Lee, J.; Kwon, T.; Choi, H. G.; Kim, Y. B.; Oh, Y. K. Light-switchable systems for remotely controlled drug delivery. J. Control. Release 2017, 267, 67–79.CrossRefGoogle Scholar
  19. [19]
    Kohman, R. E.; Cha, S. S.; Man, H. Y.; Han, X. Light-triggered release of bioactive molecules from DNA nanostructures. Nano Lett. 2016, 16, 2781–2785.CrossRefGoogle Scholar
  20. [20]
    Geng, S. Y.; Wang, Y. Z.; Wang, L. P.; Kouyama, T.; Gotoh, T.; Wada, S.; Wang, J. Y. A light-responsive self-assembly formed by a cationic azobenzene derivative and SDS as a drug delivery system. Sci. Rep. 2017, 7, 39202.CrossRefGoogle Scholar
  21. [21]
    Basuki, J. S.; Qie, F. X.; Mulet, X.; Suryadinata, R.; Vashi, A. V.; Peng, Y. Y.; Li, L. L.; Hao, X. J.; Tan, T. W.; Hughes, T. C. Photo-modulated therapeutic protein release from a hydrogel depot using visible light. Angew. Chem., Int. Ed. 2017, 56, 966–971.CrossRefGoogle Scholar
  22. [22]
    Lajunen, T.; Nurmi, R.; Kontturi, L.; Viitala, L.; Yliperttula, M.; Murtomaki, L.; Urtti, A. Light activated liposomes: Functionality and prospects in ocular drug delivery. J. Control. Release 2016, 244, 157–166.CrossRefGoogle Scholar
  23. [23]
    Sun, W. J.; Jiang, T. Y.; Lu, Y.; Reiff, M.; Mo, R.; Gu, Z. Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J. Am. Chem. Soc. 2014, 136, 14722–14725.CrossRefGoogle Scholar
  24. [24]
    Sun, W. J.; Ji, W. Y.; Hall, J. M.; Hu, Q. Y.; Wang, C.; Beisel, C. L.; Gu, Z. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem., Int. Ed. 2015, 54, 12029–12033.CrossRefGoogle Scholar
  25. [25]
    Shu, Y.; Pi, F. M.; Sharma, A.; Rajabi, M.; Haque, F.; Shu, D.; Leggas, M.; Evers, B. M.; Guo, P. X. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv. Drug Deliv. Rev. 2014, 66, 74–89.CrossRefGoogle Scholar
  26. [26]
    Jasinski, D.; Haque, F.; Binzel, D. W.; Guo, P. X. Advancement of the emerging field of RNA nanotechnology. ACS Nano 2017, 11, 1142–1164.CrossRefGoogle Scholar
  27. [27]
    Li, H.; Lee, T.; Dziubla, T.; Pi, F. M.; Guo, S. J.; Xu, J.; Li, C.; Haque, F.; Liang, X. J.; Guo, P. X. RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications. Nano Today 2015, 10, 631–655.CrossRefGoogle Scholar
  28. [28]
    Shu, Y.; Haque, F.; Shu, D.; Li, W.; Zhu, Z.; Kotb, M.; Lyubchenko, Y.; Guo, P. Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. RNA 2013, 19, 767–777.CrossRefGoogle Scholar
  29. [29]
    Haque F, Shu D, Shu Y, Shlyakhtenko L, Rychahou P, Evers M, Guo P. Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today 2012, 7, 245–257.CrossRefGoogle Scholar
  30. [30]
    Shu, D.; Shu, Y.; Haque, F.; Abdelmawla, S.; Guo, P. X. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat. Nanotechnol. 2011, 6, 658–667.CrossRefGoogle Scholar
  31. [31]
    Piao, X. J.; Wang, H. Z.; Binzel, D. W.; Guo, P. X. Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2’-F RNA, and LNA in the context of Phi29 pRNA 3WJ. RNA 2018, 24, 67–76.CrossRefGoogle Scholar
  32. [32]
    Binzel, D.; Shu, Y.; Li, H.; Sun, M. Y.; Zhang, Q. S.; Shu, D.; Guo, B.; Guo, P. X. Specific delivery of MiRNA for high efficient inhibition of prostate cancer by RNA nanotechnology. Mol. Ther. 2016, 24, 1267–1277.CrossRefGoogle Scholar
  33. [33]
    Binzel, D. W.; Khisamutdinov, E. F.; Guo, P. X. Entropy-driven one-step formation of Phi29 pRNA 3WJ from three RNA fragments. Biochemistry 2014, 53, 2221–2231.CrossRefGoogle Scholar
  34. [34]
    Jasinski, D. L.; Khisamutdinov, E. F.; Lyubchenko, Y. L.; Guo, P. X. Physicochemically tunable polyfunctionalized RNA square architecture with fluorogenic and ribozymatic properties. ACS Nano 2014, 8, 7620–7629.CrossRefGoogle Scholar
  35. [35]
    Shu, D.; Li, H.; Shu, Y.; Xiong, G. F.; Carson, W. E.; Haque, F.; Xu, R.; Guo, P. X. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 2015, 9, 9731–9740.CrossRefGoogle Scholar
  36. [36]
    Cui, D. X.; Zhang, C. L.; Liu, B.; Shu, Y.; Du, T.; Shu, D.; Wang, K.; Dai, F. P.; Liu, Y. L.; Li, C. et al. Regression of gastric cancer by systemic injection of RNA nanoparticles carrying both ligand and siRNA. Sci. Rep. 2015, 5, 10726.CrossRefGoogle Scholar
  37. [37]
    Khisamutdinov, E. F.; Jasinski, D. L.; Li, H.; Zhang, K. M.; Chiu, W.; Guo, P. X. Fabrication of RNA 3D nanoprisms for loading and protection of small RNAs and model drugs. Adv. Mater. 2016, 28, 10079–10087.CrossRefGoogle Scholar
  38. [38]
    Li, H.; Zhang, K. M.; Pi, F. M.; Guo, S. J.; Shlyakhtenko, L.; Chiu, W.; Shu, D.; Guo, P. X. Controllable self-assembly of RNA tetrahedrons with precise shape and size for cancer targeting. Adv. Mater. 2016, 28, 7501–7507.CrossRefGoogle Scholar
  39. [39]
    Xu, C. C.; Haque, F.; Jasinski, D. L.; Binzel, D. W.; Shu, D.; Guo, P. X. Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy. Cancer Lett. 2018, 414, 57–70.CrossRefGoogle Scholar
  40. [40]
    Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325–2327.Google Scholar
  41. [41]
    Spencer, C. M.; Faulds, D. Paclitaxel. Drugs 1994, 48, 794–847.CrossRefGoogle Scholar
  42. [42]
    Rowinsky, E. K.; Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med. 1995, 332, 1004–1014.CrossRefGoogle Scholar
  43. [43]
    Horwitz, S. B. Mechanism of action of Taxol. Trends Pharmacol. Sci. 1992, 13, 134–136.CrossRefGoogle Scholar
  44. [44]
    Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm. 2002, 235, 179–192.CrossRefGoogle Scholar
  45. [45]
    Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37, 1590–1598.CrossRefGoogle Scholar
  46. [46]
    Shu Y, Yin H, Rajabi M, Li H, Vieweger M, Guo S, Shu D, Guo P. RNA-based micelles: A novel platform for paclitaxel loading and delivery. J. Control. Release, 2018, 14, 17–29.CrossRefGoogle Scholar
  47. [47]
    Kim, S. C.; Kim, D. W.; Shim, Y. H.; Bang, J. S.; Oh, H. S.; Kim, S. W.; Seo, M. H. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J. Control. Release 2001, 72, 191–202.CrossRefGoogle Scholar
  48. [48]
    Bedikian, A. Y.; Plager, C.; Papadopoulos, N.; Eton, O.; Ellerhorst, J.; Smith, T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004, 14, 63–66.CrossRefGoogle Scholar
  49. [49]
    Hwu, J. R.; Lin, Y. S.; Josephrajan, T.; Hsu, M. H.; Cheng, F. Y.; Yeh, C. S.; Su, W. C.; Shieh, D. B. Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles. J. Am. Chem. Soc. 2009, 131, 66–68.CrossRefGoogle Scholar
  50. [50]
    Yoshizawa, Y.; Kono, Y.; Ogawara, K.; Kimura, T.; Higaki, K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int. J. Pharm. 2011, 412, 132–141.CrossRefGoogle Scholar
  51. [51]
    Hamaguchi, T.; Kato, K.; Yasui, H.; Morizane, C.; Ikeda, M.; Ueno, H.; Muro, K.; Yamada, Y.; Okusaka, T.; Shirao, K. et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br. J. Cancer 2007, 97, 170–176.CrossRefGoogle Scholar
  52. [52]
    Lay, C. L.; Liu, H. Q.; Tan, H. R.; Liu, Y. Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graftcarbon nanotubes for potent cancer therapeutics. Nanotechnology 2010, 21, 065101.CrossRefGoogle Scholar
  53. [53]
    Deng, J. X.; Huang, L.; Liu, F. Understanding the structure and stability of paclitaxel nanocrystals. Int. J. Pharm. 2010, 390, 242–249.CrossRefGoogle Scholar
  54. [54]
    Walter, F.; Murchie, A. I.; Lilley, D. M. J. Folding of the four-way RNA junction of the hairpin ribozyme. Biochemistry 1998, 37, 17629–17636.CrossRefGoogle Scholar
  55. [55]
    Binzel, D. W.; Khisamutdinov, E.; Vieweger, M.; Ortega, J.; Li, J. Y.; Guo, P. X. Mechanism of three-component collision to produce ultrastable pRNA three-way junction of Phi29 DNA-packaging motor by kinetic assessment. RNA 2016, 22, 1710–1718.CrossRefGoogle Scholar
  56. [56]
    Benkato, K.; O’Brien, B.; Bui, M. N.; Jasinski, D. L.; Guo, P. X.; Khisamutdinov, E. F. Evaluation of thermal stability of RNA nanoparticles by temperature gradient gel electrophoresis (TGGE) in native condition. In RNA Nanostructures. Methods in Molecular Biology, vol 1632. Bindewald, E.; Shapiro, B., Eds.; Humana Press: New York, NY, 2017; pp 123–133.Google Scholar
  57. [57]
    Lee, T. J.; Haque, F.; Shu, D.; Yoo, J. Y.; Li, H.; Yokel, R. A.; Horbinski, C.; Kim, T. H.; Kim, S. H.; Kwon, C. H. et al. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget 2015, 6, 14766–14776.Google Scholar
  58. [58]
    Tiemann, K.; Rossi, J. J. RNAi-based therapeutics–current status, challenges and prospects. EMBO Mol. Med. 2009, 1, 142–151.CrossRefGoogle Scholar
  59. [59]
    Shu, D.; Khisamutdinov, E. F.; Zhang, L.; Guo, P. X. Programmable folding of fusion RNA in vivo and in vitro driven by pRNA 3WJ motif of phi29 DNA packaging motor. Nucleic Acids Res. 2014, 42, e10.CrossRefGoogle Scholar
  60. [60]
    Kolpashchikov, D. M. Binary malachite green aptamer for fluorescent detection of nucleic acids. J. Am. Chem. Soc. 2005, 127, 12442–12443.CrossRefGoogle Scholar
  61. [61]
    Pothoulakis, G.; Ceroni, F.; Reeve, B.; Ellis, T. The spinach RNA aptamer as a characterization tool for synthetic biology. ACS Synth. Biol. 2014, 3, 182–187.CrossRefGoogle Scholar
  62. [62]
    Sassanfar, M.; Szostak, J. W. An RNA motif that binds ATP. Nature 1993, 364, 550–553.CrossRefGoogle Scholar
  63. [63]
    Srisawat, C.; Engelke, D. R. Streptavidin aptamers: Affinity tags for the study of RNAs and ribonucleoproteins. RNA 2001, 7, 632–641.CrossRefGoogle Scholar
  64. [64]
    Hoeprich, S.; Zhou, Q.; Guo, S.; Qi, G.; Wang, Y.; Guo, P. Bacterial virus Phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Gene Ther. 2003, 10, 1258–1267.CrossRefGoogle Scholar
  65. [65]
    Gaplovsky, M.; Il’ichev, Y. V.; Kamdzhilov, Y.; Kombarova, S. V.; Mac, M.; Schwörer, M. A.; Wirz, J. Photochemical reaction mechanisms of 2-nitrobenzyl compounds: 2-Nitrobenzyl alcohols form 2-nitroso hydrates by dual proton transfer. Photochem. Photobiol. Sci. 2005, 4, 33–42.CrossRefGoogle Scholar
  66. [66]
    Jasinski, D. L.; Yin, H. R.; Li, Z. F.; Guo, P. X. The hydrophobic effect from conjugated chemicals or drugs on in vivo biodistribution of RNA nanoparticles. Hum. Gene Ther., in press, DOI: 10.1089/hum.2017.054.Google Scholar
  67. [67]
    Afonin, K. A.; Bindewald, E.; Yaghoubian, A. J.; Voss, N.; Jacovetty, E.; Shapiro, B. A.; Jaeger, L. In vitro assembly of cubic RNA-based scaffolds designed in silico. Nat. Nanotechnol. 2010, 5, 676–682.CrossRefGoogle Scholar
  68. [68]
    Pi, F.; Binzel, D.; Lee, T. J.; Li, Z.; Sun, M.; Rychahou, P.; Li, H.; Haque, F.; Wang, S.; Croce, C. M. et al. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat. Nanotechnol. 2018, 13, 8.CrossRefGoogle Scholar

Copyright information

© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Congcong Xu
    • 1
    • 2
    • 3
  • Hui Li
    • 1
    • 2
    • 3
  • Kaiming Zhang
    • 4
  • Daniel W. Binzel
    • 1
    • 2
    • 3
  • Hongran Yin
    • 1
    • 2
    • 3
  • Wah Chiu
    • 4
    • 5
  • Peixuan Guo
    • 1
    • 2
    • 3
    Email author
  1. 1.Center for RNA Nanobiotechnology and NanomedicineThe Ohio State UniversityColumbusUSA
  2. 2.Division of Pharmaceutics and Pharmaceutical Chemistry, College of PharmacyThe Ohio State UniversityColumbusUSA
  3. 3.Dorothy M. Davis Heart and Lung Research Institute, College of Medicine and James Comprehensive Cancer CenterThe Ohio State UniversityColumbusUSA
  4. 4.Departments of Bioengineering, Microbiology and Immunology, and James H. Clark CenterStanford UniversityStanfordUSA
  5. 5.SLAC National Accelerator LaboratoryStanford UniversityMenlo ParkUSA

Personalised recommendations